Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?

by Jill Wechsler, pp. 55-57, 60 The industry must ensure that manufacturing systems can produce high quality and consistent therapies, efforts that may lead to comparable "subsequent entry" products.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 23 years ago

Article

Guest Editorial: Warning Letters ? A Symptom?

over 23 years ago

Article

The Importance of Freezing on Lyophilization Cycle Development

over 23 years ago

Article

Outsourcing Outlook: Using Earned-Value Analysis for Better Project Management

over 23 years ago

Article

Business Benefits of Computer Systems Validation

over 23 years ago

Article

Validation of Quantitative PCR Assays?Addressing Virus Contamination Concerns

over 23 years ago

Article

A System Developer's Approach to Validation

over 23 years ago

Article

Additional charts for the Zeid article, "Specifications and Manufacturing Change Control"

over 23 years ago

Article

Specifications and Manufacturing Change Control: A Prototypic System for Electronic Document Tracking and Management

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Inside Washington: Biotech Manufacturing ? Obstacle or Opportunity?

Articles in this issue

Newsletter

Trending on BioPharm International

Therapeutic Nucleic Acids: Advanced Solutions for Downstream Processing & Analysis

Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress

Analytics, Automation, and Quality Driving the Next Era of Drug Development